ASTELLAS PHARMA INC./ JP3942400007 /
11/7/2024 9:44:20 PM | Chg. +0.065 | Volume | Bid11/7/2024 | Ask11/7/2024 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
10.490EUR | +0.62% | 93 Turnover: 971 |
10.355Bid Size: 240 | 10.500Ask Size: 240 | 18.94 bill.EUR | - | - |
GlobeNewswire
8/14
Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD...
GlobeNewswire
8/8
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
GlobeNewswire
4/16
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Dir...
GlobeNewswire
3/19
Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degene...
GlobeNewswire
2/26
FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZenec...
GlobeNewswire
2/7
LAPIX Therapeutics Strengthens Board of Directors with Appointments of Pharmaceutical Industry Veter...
GlobeNewswire
12/11/2023
Basilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the Unit...
GlobeNewswire
10/19/2023
Basilea announces acquisition of novel clinical-stage antifungal for treatment of Aspergillus mold i...
GlobeNewswire
9/14/2023
Mineralys Therapeutics Expands its Board of Directors with Appointments of Glenn Sblendorio and Daph...
GlobeNewswire
9/11/2023
Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors